H-Cyte Announces Intent To Acquire Skindisc, Expects To Complete Within 30 Days

Sep 19, 2022•about 3 years ago

Acquiring Company

H-CYTE

Acquired Company

SkinDisc

MedicalBiotechnologyHealth Care

Description

H-CYTE, Inc. (OTCQB: HCYT), a medical biosciences company, announced today that the Company has entered into a letter of intent to acquire SkinDisc, a patent pending tissue regeneration technology, that is expected to close within the next 30 days.

Company Information

Company

H-CYTE

Location

N West Shore Blvd

About

H-CYTE is a medical biosciences company. H-CYTE’s mission is to become a leader in next-generation, cellular therapeutics for the treatment of chronic health conditions, with the ultimate goal of improving patient lives. For more information about H-CYTE, please visit www.HCYTE.com.

M&A Insights

Based on deal data

Integration timeline

70% of M&A integrations take 12-24 months to complete

Tech stack consolidation

83% of merged companies consolidate technology vendors within first year

Post-acquisition investment

Companies increase IT spending by 23% on average after acquisitions

Success factor

M&A deals with strong technology integration plans are 2.5x more likely to succeed

H-Cyte Announces Intent To Acquire Skindisc, Expects To Complete Within 30 Days

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

M&A Insights

Company Information